Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease

Korean Journal of Internal Medicine

Volumn 28, Issue 4, 2013, Pages 439-448

  Illnait, José ^a   Rodríguez, Iván ^a   Mendoza, Sarahí ^a   Fernández, Yolanda ^a   Mas, Rosa ^a   Miranda, Mirtha ^a   Piñera, Jesús ^a   Fernández, Julio César ^a   Mesa, Meilis ^a   Fernández, Lilia ^a   Carbajal, Daisy ^a   Gámez, Rafael ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Beeswax; D 002; Fatty liver; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; D 002; GAMMA GLUTAMYLTRANSFERASE; INSULIN; LIVER PROTECTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HOMEOSTATIC MODEL ASSESSMENT INDEX; HUMAN; INSULIN RESISTANCE; LIVER PROTECTION; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TOTAL ANTIOXIDANT STATUS;

BEESWAX; D-002; FATTY LIVER; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADULT; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CUBA; DOUBLE-BLIND METHOD; ENZYMES; FATTY ALCOHOLS; FATTY LIVER; FEMALE; HUMANS; INSULIN; LIPIDS; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WAXES;

EID: 84880424111     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2013.28.4.439     Document Type: Article

References (41)

1. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007;25:883-889.
2. Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M. Treating nonalcoholic fatty liver disease. Liver Int 2007;27:1157-1165.
3. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-384.
4. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010;55:560-578.
5. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-E468.
6. Kim HJ, Lee KE, Kim DJ, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-2175.
7. Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci 2007;32:453-468.
8. Caporaso N, Morisco F, Camera S, Graziani G, Donnarumma L, Ritieni A. Dietary approach in the prevention and treatment of NAFLD. Front Biosci 2012;17:2259-2268.
9. Moscatiello S, Marzocchi R, Villanova N, Bugianesi E, Marchesini G. Which treatment for nonalcoholic fatty liver disease? Mini Rev Med Chem 2008;8:767-775.
10. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
11. Hortander JC, Kwo PY, Cummings OW, Koukoulis G. Atorvastatin for the treatment of NASH. Gastroenterology 2001;120(5 Suppl 1):A544.
12. Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003;38:414-418.
13. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008;14:6395-6400.
14. Musto D, Martorelli L, Russo M, et al. Non-alcoholic hepatic steatosis: the role of policosanols in associated hyperlipidemia. Minerva Gastroenterol Dietol 2010;56:389-395.
15. Ohta Y, Ohashi K, Matsura T, Tokunaga K, Kitagawa A, Yamada K. Octacosanol attenuates disrupted hepatic reactive oxygen species metabolism associated with acute liver injury progression in rats intoxicated with carbon tetrachloride. J Clin Biochem Nutr 2008;42:118-125.
16. Mas R. Policosanol. Drugs Future 2000;25:569-586.
17. Mas R. D-002: a product obtained from beeswax. Drugs Future 2001;26:731-744.
18. Menendez R, Amor AM, Gonzalez RM, Jimenez S, Mas R. Inhibition of rat microsomal lipid peroxidation by the oral administration of D002. Braz J Med Biol Res 2000;33:85-90.
19. Molina V, Valdes S, Carbajal D, Arruzazabala L, Menendez R, Mas R. Antioxidant effect of D-002 on gastric mucosa of rats with experimentally induced injury. J Med Food 2001;4:79-83.
20. Perez Y, Oyarzabal A, Mas R, Molina V, Jimenez S. Protective effect of D-002, a mixture of beeswax alcohols, against indomethacin-induced gastric ulcers and mechanism of action. J Nat Med 2013;67:182-189.
21. Menendez R, Mas R, Illnait J, et al. Effects of D-002 on lipid peroxidation in older subjects. J Med Food 2001;4:71-77.
22. Lopez E, Illnait J, Molina V, et al. Effects of D-002 (beeswax alcohols) on lipid peroxidation in middle-aged and older subjects. Lat Am J Pharm 2008;27:695-703.
23. Rodriguez I, Illnait J, Molina V, et al. Comparison of the antioxidant effects of D-002 (beeswax alcohols) and grape seed extract (GSE) on plasma oxidative variables in healthy subjects. Lat Am J Pharm 2010;29:255-262.
24. Mendoza S, Noa M, Perez Y, Mas R. Preventive effect of D-002, a mixture of long-chain alcohols from beeswax, on the liver damage induced with CCl4 in rats. J Med Food 2007;10:379-383.
25. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007;47:711-717.
26. Csendes P, Paolinelli P, Bussel D, Venturelli V, Rodriguez J. Higado graso: ultrasonido y correlación anatomopatológica. Rev Chil Radiol 2004;10:50-52.
27. Rodriguez I, Illnait J, Terry H, et al. Effects of Abexol (beeswax alcohols) on gastrointestinal symptoms in middle-aged and older subjects. Rev CENIC Cien Biol 2009;40:147-154.
28. Graif M, Yanuka M, Baraz M, et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol 2000;35:319-324.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
30. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141-150.
31. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004;53:1020-1023.
32. Hsiao PJ, Kuo KK, Shin SJ, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 2007;22:2118-2123.
33. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.
34. Petta S, Handberg A, Craxi A. Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. Curr Pharm Des. 2013 Feb 4 [Epub].
35. Ruales F, Barbano J, Gomez E. Correlation between fatty infiltration of the liver and body mass index, triglycerides and transaminases. Acta Gastroenterol Latinoam 2012;42:278-284.
36. Barsic N, Lerotic I, Smircic-Duvnjak L, Tomasic V, Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2012;18:3945-3954.
37. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-131.
38. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25:1135-1141.
39. Singh DK, Li L, Porter TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 2006;318:1020-1026.
40. Messina D, Perez Elizalde R, Soto C, Uvilla A, Lopez Laur JD, Lopez Fontana C. High intake of lycopene together with low intake of red meat increases the total antioxidant status. Arch Latinoam Nutr 2012;62:15-22.
41. Ozgur P, Huseyin B, Ferhat C, Huseyin K, Nuri DB. Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol 2013;5:33-39.